Premium
Phase II Study of Mitoxantrone in Advanced or Metastatic Endometrial Carcinoma
Author(s) -
Boadle D. J.,
Tattersall M. H. N.
Publication year - 1987
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1987.tb01023.x
Subject(s) - mitoxantrone , medicine , chemotherapy , carcinoma , oncology , phases of clinical research , metastatic carcinoma , chlorambucil , cyclophosphamide
Summary: Mitoxantrone was administered to 12 patients with advanced or recurrent endometrial carcinoma of whom only I had received prior chemotherapy (chlorambucil). The drug was given every 21 days, the initial dose of either 12mg/m 1 or 14mg/m 1 being decided by the patient's age, timing of prior radiotherapy, tolerance of prior chemotherapy and baseline haematological parameters. One partial response was observed in the 11 patients evaluable for assessment of response. Mitoxantrone was well tolerated with the major toxicity being myelosuppression, particularly granulocytopenia. With the observed response rate of 9%, we conclude that mitoxantrone does not have significant activity in endometrial carcinoma.